secwatch.observer — SEC 8-K summary
======================================

Issuer:     Nexalin Technology, Inc. (NXL)
CIK:        0001527352
Form:       8-K
Filed at:   2024-09-19T23:59:59+00:00
Accession:  0001829126-24-006349
Event type: leadership
Sentiment:  neutral
Materiality: 0.35
Item codes: 5.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Nexalin appoints Carolyn Shelton as SVP Quality, Regulatory & Clinical Affairs
------------------------------------------------------------------------------

- Carolyn Shelton appointed SVP Quality, Regulatory and Clinical Affairs effective Sept 16, 2024.
- Base salary of $300,000; annual discretionary bonus of $40,000 based on milestones.
- Stock options valued at $60,000 under 2023 Equity Incentive Plan, vesting equally over 3 years from Sept 16, 2025.
- Prior roles include VP Regulatory/Quality at Openwater Health, Advanced Sterilization Products, and Medtronic.
- Relocation expenses up to $5,000; five weeks paid time off per year.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1527352/000182912624006349/0001829126-24-006349-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1527352/000182912624006349/nexalintec_8k.htm
  HTML page:      https://secwatch.observer/filing/0001829126-24-006349

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer